A team of physician-scientists are now enrolling patients in a clinical trial to evaluate a common anti-clotting drug for the treatment of COVID-19-positive patients with ARDS. The newly launched trial follows a special report the team published that suggested the use of a drug called tPA could reduce deaths among patients with ARDS as a complication of COVID-19.